Sanara MedTech Inc. Announces Proposed Public Offering of Common Stock FORT WORTH, TX / ACCESSWIRE /

Sanara MedTech Inc. Announces Proposed Public Offering of Common

FORT WORTH, TX / ACCESSWIRE / February 11, 2021 / Sanara

Based in Fort Worth, Texas, Sanara MedTech Inc.

( Sanara, the Company, we,

our or us ) (NASDAQ: SMTI), a provider

of wound and skin care products dedicated to improving patient

outcomes, today announced that it intends to offer shares of its

common stock in an underwritten public offering. In addition,

Sanara intends to grant the underwriters a 30-day option to

purchase up to an additional 15% of the number of shares of its

common stock offered in the public offering. The proposed offering

is subject to market and other conditions, and there can be no

assurance as to whether or when the offering may be completed, or

as to the actual size or terms of the offering.

Cantor Fitzgerald & Co. is acting as the sole book-running

manager for the proposed offering.

The shares of common stock are being offered by the Company

pursuant to a registration statement previously filed with and

declared effective by the Securities and Exchange Commission (the

"SEC"). The offering will be made only by means of a prospectus,

consisting of a prospectus supplement and an accompanying

prospectus. A preliminary prospectus supplement and an accompanying

prospectus relating to the offering will be filed with the SEC and

will be available on the SEC's website located at

http://www.sec.gov. Copies of the preliminary prospectus supplement

and the accompanying prospectus, when filed with the SEC, may also

be obtained from Cantor Fitzgerald & Co., 499 Park Avenue, 6th

Floor, New York, NY 10022, Attn: Capital Markets Department, or by

email at prospectus@cantor.com.

This press release shall not constitute an offer to sell or the

solicitation of an offer to buy these securities, nor shall there

be any sale of these securities, in any state or jurisdiction in

which such an offer, solicitation or sale would be unlawful prior

to registration or qualification under the securities laws of any

such state or jurisdiction.

About Sanara MedTech Inc.

With a focus on improving patient outcomes through evidence-based

healing solutions and services, Sanara MedTech Inc. markets and

distributes wound and skin care products and is seeking to offer

wound care and dermatology virtual consultation services via

telemedicine to physicians, hospitals, clinics, and all post-acute

care settings. Sanara's products are primarily sold in the

North American advanced wound care and surgical tissue repair

markets. Sanara MedTech markets and distributes CellerateRX

Surgical Activated Collagen to the surgical markets as well

as the following products to the wound care market:

BIAK S Antimicrobial Skin and Wound Cleanser,

BIAK S Antimicrobial Wound Gel, BIAK S

Antimicrobial Skin and Wound Irrigation Solution, and HYCOL

Hydrolyzed Collagen Powder and Gel. We are constantly seeking

long-term strategic partnerships with a focus on products and

technologies that improve outcomes at a lower overall cost. In

addition, Sanara is actively seeking to expand within its six focus

areas of wound and skin care for the acute, post-acute, and

surgical markets. The focus areas are debridement, biofilm removal,

hydrolyzed collagen, advanced biologics, negative pressure wound

therapy adjunct products, and the oxygen delivery system segment of

the healthcare industry.

Forward-Looking Statements

The statements in this press release that do not constitute

historical facts are forward-looking statements,

within the meaning of and subject to the safe harbor created by the

Private Securities Litigation Reform Act of 1995. These statements

may be identified by terms such as may,

will, would, should,

expect, plan, anticipate,

could, intend, target,

project, contemplates,

believes, estimates,

predicts, preliminary,

potential or continue or the negatives

of these terms, variations of these terms or other similar

expressions. These forward-looking statements include statements

regarding the proposed offering, the development of new products

and expansion of the Company's business in telehealth and

wound care. These items involve risks, contingencies and

uncertainties such as the extent of product demand, market and

customer acceptance, the effect of economic conditions,

competition, pricing, the ability to consummate and integrate

acquisitions, and other risks, contingencies and uncertainties

detailed in the Company's SEC filings, which could cause the

Company's actual operating results, performance or business

plans or prospects to differ materially from those expressed in, or

implied by these statements.

All forward-looking statements speak only as of the date on which

they are made, and the Company undertakes no obligation to revise

any of these statements to reflect the future circumstances or the

occurrence of unanticipated events, except as required by

applicable securities laws.

Callon Nichols, Director of Investor Relations

SOURCE: Sanara MedTech Inc.